RXi Pharmaceuticals Corp Stock Nasdaq
Equities
US74979C5013
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 75M | Capitalization | 3.61M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | 47M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.05 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
0.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Director/Board Member | 73 | 22-05-01 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 13-04-17 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |